Advanced Malignancies | Norton Healthcare

Indication: Advanced Malignancies

An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) in subjects with advanced cancer

Sub-indication: Miscellaneous Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Vincerx Pharma, Inc

Email for more information: MISC-NCIResearch@Nortonhealthcare.org Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.